Business News • PR NewsWire • Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues

Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues

Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues

EAST HANOVER, N.J., May 5, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control....

View More : http://www.prnewswire.com/news-releases/novartis-drug-signifor-lar-shows-superior-efficacy-in-acromegaly-patients-not-co...

Releted News by prnewswire

Global Brands, Innovators and Business Leaders Arrive at Ektron's User Conference to Explore the Power of Innovation

Assurex Health Releases Enhanced Pharmacogenomic Test to Help Clinicians Select Medications for Depression, Anxiety and PTSD

Exar Corporation Announces Fourth Quarter and Fiscal 2014 Results